New Peer-Reviewed Publication Shows Multi-Omic AI-Powered Blood Test Detects Ovarian Cancer with High Accuracy in Symptomatic Women
AOA Dx (AOA), a company pioneering blood-based diagnostics for early cancer detection, has published peer-reviewed evidence demonstrating high accuracy in detecting ovarian cancer in symptomatic women, a population where early diagnosis is critical but often delayed.
AOA Dx Appoints Lipidomics Leader Dr. Kim Ekroos to Scientific Advisory Board to Advance Multi-Omic Cancer Diagnostic Platform
AOA Dx has appointed lipidomics pioneer Dr. Kim Ekroos to its Scientific Advisory Board to support the advancement of its multi-omic diagnostic platform.
Sonrai and AOA Dx Partner to Accelerate Development of Ovarian Cancer Test
Strategic collaboration leverages Sonrai’s AI-powered platform to support the development of AOA Dx’s multi-omic diagnostic test for ovarian cancer.
AOA Dx Demonstrates High Accuracy in AI-Powered Blood Test for Ovarian Cancer Detection in 1,000 Symptomatic Patient Samples
AOA Dx presented new data at the 2025 AACR Annual Meeting demonstrating high accuracy in early detection of ovarian cancer using its AI-powered multi-omic platform. In collaboration with CU Anschutz Ovarian Cancer Innovations Group (OCIG) and The University of Manchester, the platform achieved AUCs over 90% across approximately 1,000 real-world symptomatic patient samples, outperforming traditional biomarkers like CA125. These results highlight the potential of AOA Dx’s liquid biopsy to aid earlier, more accurate diagnosis and improve outcomes for women worldwide.
AOA Dx Joins BLOODPAC to Accelerate Early Detection of Ovarian Cancer with Liquid Biopsy Innovations
AOA Dx is excited to join the BLOODPAC Consortium, a public-private initiative dedicated to advancing liquid biopsy technologies for cancer detection. Through this partnership, AOA Dx will contribute its expertise in lipidomics and multi-omics to help establish standards for early detection assays, particularly in ovarian cancer. With a commitment to scientific collaboration, AOA Dx plans to share its research on gangliosides, lipids, and proteins, furthering the integration of liquid biopsy into clinical practice.
AOA Dx to Present Latest Research on Tumor-Marker Gangliosides for Early Detection of Ovarian Cancer at International Liquid Biopsy Conference
AOA Dx will showcase its latest research at the International Society of Liquid Biopsy conference (November 23–25, 2024), presenting findings from the study “Identification of Tumor-Marker Gangliosides in Serum for Early-Stage Cancer Diagnosis.” This research underscores the promise of tumor-marker gangliosides (TMGs) as biomarkers for early ovarian cancer detection.
AOA Dx Welcomes Abigail McElhinny, PhD, as Chief Scientific Officer
AOA Dx is announcing the addition of a Chief Scientific Officer, Dr. Abigail McElhinny. Dr. McElhinny comes from a background in leadership in oncology diagnostics. This experience will be transformative for the AOA Dx team.
CEO and Co-Founder Oriana Papin-Zoghbi selected for the TITAN 100 list, recognizing the top 100 CEOs & C-level executives in Colorado
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the TITAN 100 list. The list highlights Colorado’s most accomplished business leaders in their industry.
AOA Dx secures $17 Million to revolutionize the diagnosis of ovarian cancer with early detection and high accuracy, and to expand their GlycoLocate™ Platform to target a broader range of cancers
AOA Dx is announcing an oversubscribed $17 million round led by Good Growth Capital with participation from leading investors including RH Capital, Y Combinator, Astia Fund, Adaptive Capital Partners, Gore Range Capital, LongeVC, The Helm, VU Venture Partners, and FemHealth Ventures, along with strategic diagnostic investors, including Labcorp Venture Fund. Several funds invested for the second time, underpinning the continuous success of AOA Dx across the last year.
CEO and Co-Founder Oriana Papin-Zoghbi selected for Bloomberg New Economy Catalysts
AOA Dx is excited to announce that our CEO, Oriana Papin-Zoghbi, has been selected for the Bloomberg New Economy Catalysts and will represent the women’s health industry at the Bloomberg New Economy Forum in Singapore.